Takeda Pharmaceutical Co Ltd ADR (TAK) - Total Liabilities
Based on the latest financial reports, Takeda Pharmaceutical Co Ltd ADR (TAK) has total liabilities worth $7.77 Trillion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Takeda Pharmaceutical Co Ltd ADR long-term investment intensity to see how much of total assets are deployed in long-term investments.
Takeda Pharmaceutical Co Ltd ADR - Total Liabilities Trend (2001–2025)
This chart illustrates how Takeda Pharmaceutical Co Ltd ADR's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see TAK total assets.
Takeda Pharmaceutical Co Ltd ADR Competitors by Total Liabilities
The table below lists competitors of Takeda Pharmaceutical Co Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Investor AB ser. A
ST:INVE-A
|
Sweden | Skr163.19 Billion |
|
Alimentation Couchen Tard Inc A
TO:ATD
|
Canada | CA$25.17 Billion |
|
Ford Motor Company
NYSE:F
|
USA | $249.78 Billion |
|
Target Corporation
NYSE:TGT
|
USA | $44.49 Billion |
|
Diamondback Energy Inc
NASDAQ:FANG
|
USA | $28.09 Billion |
|
VOLVO B (FRIA) UNSP.ADR
F:VOL4
|
Germany | €491.70 Billion |
|
SINGAP.TELE. ADR NEW06/10
F:SIT
|
Germany | €20.53 Billion |
|
Infosys Ltd ADR
NYSE:INFY
|
USA | $6.68 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Takeda Pharmaceutical Co Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See TAK equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.25 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Takeda Pharmaceutical Co Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Takeda Pharmaceutical Co Ltd ADR (2001–2025)
The table below shows the annual total liabilities of Takeda Pharmaceutical Co Ltd ADR from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $7.31 Trillion | -6.67% |
| 2024-03-31 | $7.83 Trillion | +3.05% |
| 2023-03-31 | $7.60 Trillion | +1.45% |
| 2022-03-31 | $7.49 Trillion | -3.11% |
| 2021-03-31 | $7.74 Trillion | -4.43% |
| 2020-03-31 | $8.09 Trillion | -7.06% |
| 2019-03-31 | $8.71 Trillion | +316.87% |
| 2018-03-31 | $2.09 Trillion | -13.20% |
| 2017-03-31 | $2.41 Trillion | +32.76% |
| 2016-03-31 | $1.81 Trillion | -13.26% |
| 2015-03-31 | $2.09 Trillion | +3.03% |
| 2014-03-31 | $2.03 Trillion | +17.10% |
| 2013-03-31 | $1.73 Trillion | +15.09% |
| 2012-03-31 | $1.51 Trillion | +131.65% |
| 2011-03-31 | $649.75 Billion | -1.33% |
| 2010-03-31 | $658.53 Billion | -6.77% |
| 2009-03-31 | $706.35 Billion | +34.10% |
| 2008-03-31 | $526.75 Billion | -13.84% |
| 2007-03-31 | $611.38 Billion | -11.89% |
| 2006-03-31 | $693.87 Billion | +27.54% |
| 2005-03-31 | $544.02 Billion | -1.92% |
| 2004-03-31 | $554.65 Billion | +12.82% |
| 2003-03-31 | $491.64 Billion | -2.82% |
| 2002-03-31 | $505.88 Billion | +1.65% |
| 2001-03-31 | $497.69 Billion | -- |
About Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more